<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529711</url>
  </required_header>
  <id_info>
    <org_study_id>001/IGK-KAL/DNA/04</org_study_id>
    <nct_id>NCT00529711</nct_id>
  </id_info>
  <brief_title>The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients</brief_title>
  <official_title>The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innogene Kalbiotech Pte. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innogene Kalbiotech Pte. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous clinical trials with 11.2% Hypertonic Ringer's Lactate in post-operative CABG
      subjects have shown an increase in several cardiac performance parameters, with lesser volume
      of resuscitation fluid required to reach circulation volume, as compared to Sodium
      Chloride.It also does not cause hyperchloremic acidosis, which is of value in treating shock
      patients.

      The primary objectives of this prospective, randomized, open-label trial are to evaluate the
      clinical efficacy of hypertonic lactate in comparison to Ringer's lactate to maintain
      hemodynamic stability in intra- and post-CABG subjects in relation to hemodynamic status and
      body fluid balance, as well as to assess its safety in terms of lab parameters and occurrence
      of adverse events.The secondary objectives are to evaluate comparative clinical efficacy of
      the two fluids in relation to reduction in concomitant drug utilization, duration of
      ventilator usage, length of stay in ICU as well as total duration of hospitalization and
      neurocognitive status upto a period of 1 year post-CABG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Details provided in summary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamic status</measure>
    <time_frame>During and 12 hours after CABG surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of hypertonic sodium lactate for maintaining hemodynamic stability</measure>
    <time_frame>During and 12 hours after CABG surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Low Cardiac Output</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertonic lactate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ringer's lactate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic lactate</intervention_name>
    <description>Solution given parenterally as follows:
Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Totilac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ringer's lactate</intervention_name>
    <description>Solution given parenterally as follows:
Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  45 to 80 years

          -  CABG patients with on or off pump procedure

          -  Ejection fraction &lt; 50%

          -  Given informed consent

        Exclusion Criteria:

          -  Combined operations

          -  Severe arrhythmia(VT, AF rapid response, heart blocks) and severe hemodynamic
             imbalance

          -  Severe bleeding and/or re-operation

          -  Hypernatremia &gt; 155 mMol/L

          -  Severe liver failure(SGOT, SGPT 2x normal)

          -  Severe renal failure(Creatinine &gt; 2 mg. %)

          -  Major diseases(eg. cancer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Leverve, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, INSERM-E0221-Bioenergetique Fondamentale et appliquee, Universite Joseph Fourier, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cardiac Center, Department of Surgery and Intensive Care Unit, Harapan Kita Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>114210</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <last_update_submitted>September 12, 2007</last_update_submitted>
  <last_update_submitted_qc>September 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2007</last_update_posted>
  <keyword>coronary</keyword>
  <keyword>artery</keyword>
  <keyword>bypass</keyword>
  <keyword>grafting</keyword>
  <keyword>IV</keyword>
  <keyword>cardiac output</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiac Output, Low</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

